Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata

August 2023 in “ JAMA Dermatology ”

Justin Ko, Tiffany T. Mayo, Wilma F. Bergfeld, Yves Dutronc, Guanglei Yu, Susan Ball, Najwa Somani, Brittany G. Craiglow

baricitinib alopecia areata Janus kinase 1/2 inhibitor scalp coverage eyebrow regrowth eyelash regrowth AA JAK inhibitor

TLDR Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.

The document presents a pooled analysis of two phase 3 randomized clinical trials (BRAVE-AA1 and BRAVE-AA2) involving 1200 adult patients with severe alopecia areata (AA). The study found that 25% of patients who did not respond to a 2 mg dose of baricitinib (a Janus kinase 1/2 inhibitor) showed significant hair regrowth when the dose was increased to 4 mg. Specifically, these patients achieved at least 80% scalp coverage by week 76. Additionally, response rates for clinician-reported outcome scores for eyebrows and eyelashes also increased. The study concludes that patients with severe AA not achieving successful regrowth of scalp hair with baricitinib, 2 mg, may benefit from uptitration to baricitinib, 4 mg.

View this study on doi.org →

Discuss this study in the Community →

Research cited in this study

7 / 7 results

research Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2

1 citations , September 2023 in “Dermatology and Therapy”

Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.

research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials

20 citations , March 2023 in “American Journal of Clinical Dermatology”

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

research Integrated Safety Analysis of Baricitinib in Adults With Severe Alopecia Areata From Two Randomized Clinical Trials

25 citations , November 2022 in “British journal of dermatology/British journal of dermatology, Supplement”

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

research Efficacy of Baricitinib in Patients With Various Degrees of Alopecia Areata Severity: Results From Brave-AA1 and Brave-AA2

4 citations , September 2022 in “Journal of The American Academy of Dermatology”

Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.

research Two Phase 3 Trials of Baricitinib for Alopecia Areata

148 citations , March 2022 in “The New England Journal of Medicine”

Baricitinib was effective in treating alopecia areata in two major trials.

‘You Lose Your Hair, What’s the Big Deal?’ I Was So Embarrassed, I Was So Self-Conscious, I Was So Depressed: A Qualitative Interview Study to Understand the Psychosocial Burden of Alopecia Areata

research ‘You Lose Your Hair, What’s the Big Deal?’ I Was So Embarrassed, I Was So Self-Conscious, I Was So Depressed: A Qualitative Interview Study to Understand the Psychosocial Burden of Alopecia Areata

30 citations , September 2020 in “Journal of Patient-Reported Outcomes”

Alopecia Areata (AA) causes significant emotional distress, including feelings of embarrassment, depression, and anxiety, and impacts social interactions and daily activities.

research Health-Related Quality of Life Among Patients With Alopecia Areata: A Systematic Review

95 citations , July 2016 in “Journal of The American Academy of Dermatology”

People with alopecia areata, a skin disease, generally have a poor quality of life, especially if more of their scalp is affected.